Top Page
MedAdvisor Limited
(Sydney:MDR)
MedAdvisor Limited (MDR) vs. iShares MSCI Australia ETF (EWA)
MedAdvisor Limited Business Overview & Revenue Model
MedAdvisor Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 62.99M | 62.99M | 122.11M | 97.96M | 67.75M | 38.77M |
| Gross Profit | 1.60M | 3.97M | 23.63M | 12.59M | -1.84M | -6.06M |
| EBITDA | -11.76M | -11.93M | 7.05M | -3.03M | -11.29M | -14.93M |
| Net Income | -63.32M | -60.21M | 792.13K | -11.31M | -17.35M | -13.95M |
Balance Sheet | ||||||
| Total Assets | 39.84M | 39.84M | 98.78M | 95.91M | 78.44M | 80.92M |
| Cash, Cash Equivalents and Short-Term Investments | 10.30M | 10.30M | 15.58M | 14.20M | 7.58M | 7.15M |
| Total Debt | 17.40M | 17.40M | 12.61M | 13.09M | 13.41M | 9.16M |
| Total Liabilities | 41.46M | 41.46M | 47.20M | 47.45M | 43.89M | 32.07M |
| Stockholders Equity | -1.62M | -1.62M | 51.58M | 48.46M | 34.55M | 48.45M |
Cash Flow | ||||||
| Free Cash Flow | -14.37M | -14.37M | 3.35M | -1.63M | -548.13K | -12.94M |
| Operating Cash Flow | -14.37M | -14.37M | 5.19M | -1.45M | -236.32K | -12.54M |
| Investing Cash Flow | -2.18M | -2.18M | -2.80M | -3.23M | -290.79K | -43.36M |
| Financing Cash Flow | 11.34M | 11.34M | -831.97K | 12.42M | 1.86M | 51.24M |
MedAdvisor Limited Technical Analysis
MedAdvisor Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | AU$127.58M | 79.17 | 1.89% | ― | 10.06% | ― | |
| ― | AU$87.68M | ― | -8647.54% | ― | 25.98% | 21.43% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | AU$42.73M | ― | -81.30% | ― | -36.68% | 79.41% | |
| ― | AU$61.03M | -9.86 | -13.83% | ― | 3.61% | -17.03% | |
| ― | AU$17.71M | 110.00 | -240.60% | ― | -48.41% | -7200.00% |
MedAdvisor Limited Corporate Events
MedAdvisor Limited has announced the application for quotation of 432,902 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to leverage financial instruments to support its operations and growth within the digital health sector, potentially impacting its market position and offering opportunities for stakeholders.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
MedAdvisor Limited has released a Q1 FY26 investor presentation, emphasizing that the information provided is for general purposes and not intended as financial advice or an investment offer. The presentation underscores the importance of independent assessment by potential investors, highlighting the uncertainties and risks associated with forward-looking statements. The company advises recipients to comply with applicable legal and regulatory requirements and stresses that the presentation is not an offer to sell securities in jurisdictions where it is prohibited.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
MedAdvisor Limited, a company listed on the Australian Securities Exchange (ASX) under the ticker MDR, will have its trading suspension lifted. This follows the submission of its annual financial report, allowing trading to resume on October 10, 2025, which may positively impact the company’s market presence and stakeholder confidence.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
MedAdvisor Limited has released its annual report for the fiscal year ending June 30, 2025. The report highlights the company’s continued efforts to strengthen its market position through technological advancements in medication management. The listing of its shares on the Australian Securities Exchange underscores its commitment to transparency and growth, potentially benefiting stakeholders by enhancing shareholder value and expanding its market reach.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
MedAdvisor Limited announced its 2025 Annual General Meeting will be held virtually on November 26, 2025, where an election of directors will take place. The announcement highlights the company’s ongoing governance processes and may impact its leadership structure, potentially influencing its strategic direction and stakeholder relations.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
MedAdvisor Limited announced that its securities have been suspended from quotation on the ASX due to the company’s failure to submit its FY25 Financial Report by the deadline. The company plans to lodge the audited report during the week starting 6 October 2025. This suspension could impact the company’s market perception and stakeholder confidence, highlighting the importance of timely financial reporting.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
MedAdvisor Limited announced the quotation of 7,084,545 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective from September 9, 2025. This move is part of the company’s strategy to enhance its market presence and potentially increase liquidity, reflecting its ongoing efforts to strengthen its financial position and operational capabilities in the digital health sector.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
MedAdvisor Limited has announced the relocation of its registered office and principal place of business to a new address in Camberwell, Victoria, effective from September 3, 2025. This move is part of the company’s ongoing efforts to enhance its operational efficiency and maintain its leadership position in the pharmacy-driven patient engagement industry.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
MedAdvisor Limited announced the cessation of Jim Xenos as a director, effective from August 29, 2025. This change in the board may impact the company’s strategic direction and stakeholder relations, given Mr. Xenos’s significant interests in the company, including 42,857 fully paid ordinary shares and 500,000 unlisted options.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
MedAdvisor Limited has announced the appointment of Sean Slattery as a new director, effective August 29, 2025. This development is part of the company’s strategic efforts to strengthen its leadership team, although the newly appointed director currently holds no relevant interests in the company’s securities. This appointment is expected to enhance MedAdvisor’s governance and potentially impact its strategic direction in the healthcare technology sector.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
MedAdvisor Limited announced the cessation of Kevin Hutchinson as a director, effective August 29, 2025. As part of this announcement, it was disclosed that Hutchinson held 2,000,000 unlisted options and 393,943 fully paid ordinary shares. This change in directorship may influence the company’s strategic direction and stakeholder confidence.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
MedAdvisor Limited reported a significant decline in its financial performance for FY25, with revenue from continuing operations dropping by 36% due to underperformance in US health programs. The company has sold its ANZ business division to Jonas Software AUS, aiming to focus on strengthening its US operations through cost reductions and platform development. Despite a challenging year, MedAdvisor is committed to maximizing shareholder value by restructuring its US commercial operations and continuing its Transformation 360° initiative.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
MedAdvisor Limited reported a significant financial downturn for the year ending June 30, 2025, with revenues from ordinary activities decreasing by 36% to approximately $63 million. The company experienced a substantial loss of over $60 million, a stark contrast to the previous year’s profit of $792,133, indicating severe financial challenges. No dividends were declared for the current or previous financial periods, highlighting the company’s focus on stabilizing its financial position. This downturn could impact MedAdvisor’s market positioning and stakeholder confidence, necessitating strategic adjustments to address the financial losses.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
MedAdvisor Limited announced board changes following the sale of its ANZ business, reflecting a significant change in the company’s scale. Non-Executive Directors Jim Xenos and Kevin Hutchinson have stepped down, with Hutchinson continuing in an advisory role for the US strategic review. Sean Slattery, the recently appointed CFO, joins the board as an Executive Director, bringing extensive financial expertise and experience in US operations. These changes aim to align the board with the company’s current scale and geographic focus, as MedAdvisor continues to explore strategic options.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
MedAdvisor Limited announced the results of its General Meeting, where resolutions 1 to 5 were passed, while resolutions concerning retention benefits for key executives were not approved. This outcome reflects shareholder engagement and may influence the company’s executive compensation strategy and stakeholder relations.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
MedAdvisor Limited announced an addendum to its Quarterly Activities Report for the fourth quarter of FY25, highlighting a payment of A$437k to related parties that was omitted from the initial report. This disclosure ensures transparency in financial reporting and may impact stakeholder trust and compliance with ASX regulations.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
MedAdvisor Limited’s recent investor presentation outlines general information about the company’s current standing and future prospects. The presentation emphasizes that it is not a formal offer or financial advice, highlighting the inherent risks and uncertainties in forward-looking statements. Stakeholders are advised to conduct independent assessments of MedAdvisor’s market position and potential future performance, as the presentation is not a substitute for detailed investment analysis.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
MedAdvisor Limited reported a decline in revenue and gross profit for the fourth quarter and full fiscal year 2025, attributed to budgetary pressures and delayed health program rollouts. Despite these challenges, the company completed a successful capital raise and accelerated its Transformation 360 initiative to improve future performance. The sale of its ANZ business to Jonas Software for $35 million has left MedAdvisor debt-free, and the company is considering strategic options, including a potential sale of its US business. The deferred revenue and a strong pipeline of US$125 million provide confidence for a solid first half of fiscal year 2026.
The most recent analyst rating on (AU:MDR) stock is a Buy with a A$0.45 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
MedAdvisor Limited has announced a webinar for the presentation of its 4Q FY25 results, to be delivered by CEO Rick Ratliff and incoming CFO Sean Slattery. This event, scheduled for July 31, 2025, will provide insights into the company’s performance and future outlook, potentially impacting its operations and stakeholder interests.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.